13.02.2015 • News

Germany’s Merck and FlexEnable Find Plastic LCD

German chemical and pharmaceuticals producer Merck KGaA and its UK cooperation partner, flexible electronics specialist FlexEnable, a unit of Plastic Logic, have developed a plastic LCD that substitutes organic transistors on a plastic sheet for glass.

This new development offers multiple benefits, Merck said. In particular, plastic LCDs have the potential to make products ten times thinner, more than ten times lighter, and cheaper than conventional glass-based displays, while delivering differentiating product benefits of being shatterproof and even conformal.

The demonstrator said to have been developed in a very short time frame combines the key benefits of organic transistor technology (OTFT), including superior quality and yield. Ultimately, Merck said, it shows a route to low-cost solutions for volume manufacturing with LCDs, the dominant display technology in the market today.

FlexEnable has now demonstrated the world's first plastic LCD with active-matrix in-plane switching (IPS), using the UK company's OTFT array with liquid crystal (LC) and organic semiconductor materials produced by Merck.

While the first demonstrator employs an IPS mode, the developers believe the concept will be equally attractive for many other LC modes and applications such as e-readers, dynamic public signage and advertising.

In addition to Merck and FlexEnable, other project partners included display technology experts from the institute for large area microelectronics at Germany's University of Stuttgart, German plastic film supplier LOFO High Tech Film, specialized resist supplier Micro Resist Technology, also of Germany, and Israel-based backlight supplier Etkes and Sons. The project was co-funded by the EU's Seventh Framework Program.

Company

Logo:

Merck KGaA

Frankfurter Str. 250
64293 Darmstadt
Germany

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read